Skip to content

The University of Texas MD Anderson Cancer Center

Back

An innovative cancer center making big strides in cancer immunotherapy

The University of Texas MD Anderson Cancer Center has emerged as a leader in cancer immunotherapy. Launched in 2012, the institution’s cancer Moon Shots Program, an ambitious effort to reduce cancer deaths and suffering by more rapidly developing advances based on scientific discoveries, includes a major emphasis on immunotherapy. With immune monitoring and scientific collaboration, the immunotherapy platform supports more than 100 clinical trials. The Parker Institute provides stable funding, access to cutting-edge technologies and an extended network of experts to help MD Anderson advance immunotherapy research to benefit cancer patients.

Research Focuses

Best in Class T-Cells

Advance the next generation of T-cell therapies to provide targeted, safe, long-lasting treatments that can conquer cancer.

Checkpoint Blockade Response

Uncover the reasons why some patients respond to immunotherapy while others may not, in order to overcome cancer drug resistance.

Tumor Antigen Discovery

Pinpoint novel cancer cell markers that will become the foundation for new therapies and personalized treatments.

Get Email Updates